Isorhamnetin alleviates diet induced MASLD in mice by modulating gut microbiota and bile acid metabolism - PubMed
6 hours ago
- #Gut Microbiota
- #Isorhamnetin
- #MASLD
- Isorhamnetin (ISO) alleviates diet-induced MASLD in mice by modulating gut microbiota and bile acid metabolism.
- ISO reduces body weight and hepatic lipid content in a dose-dependent manner, inhibiting lipid synthesis and promoting lipid oxidation.
- ISO reshapes gut microbiota, increasing beneficial bacteria like Lachnospiraceae, Oscillospiraceae, and Ruminococcaceae.
- Changes in gut microbiota alter bile acid pool composition, increasing primary and conjugated bile acids.
- ISO activates the hepatic-ileal FXR signaling axis, accelerating enterohepatic bile acid circulation and reducing dietary fat absorption.
- ISO enhances intestinal barrier integrity and alleviates hepatic inflammation.
- Fecal microbiota transplantation from ISO-treated mice partially reproduces metabolic benefits.
- Molecular dynamics simulations confirm ISO interacts with FXR, enhancing FXR signaling.
- ISO shows potential as a mild, multi-target natural therapeutic for MASLD.